The group met approximately every 6 weeks during the development of the guideline. At the start of the guideline development process all committee members declared interests including consultancies, fee-paid work, shareholdings, fellowships and support from the healthcare industry. At all subsequent committee meetings, members declared arising conflicts of interest. Members were either required to withdraw completely or for part of the discussion if their declared interest made it appropriate. The details of declared interests and the actions taken are shown in appendix L. Staff from the NGC provided methodological support and guidance for the development process. The team working on the guideline included a project manager, systematic reviewers (research fellows), health economists and information specialists. They undertook systematic searches of the literature, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate and drafted the guideline in collaboration with the committee. 3.3.1 What this guideline covers Groups that will be covered Adults (18 and over) with symptoms or a diagnosis of chronic heart failure (including heart failure with reduced ejection fraction and heart failure with preserved ejection fraction). Areas from the published guideline that will be updated Diagnosing heart failure. o Role of circulating biomarkers (including natriuretic peptides). o Echocardiography and cardiac MRI. Managing chronic heart failure. o Initiation and sequencing of pharmacological therapies including: Isosorbide/hydralazine. Angiotensin-II receptor antagonists (ARBs). Mineralocorticoid receptor antagonists o Fluid balance (optimum fluid and salt intake). Rehabilitation (including Home-based rehabilitation packages that include an exercise element). Monitoring heart failure. o Role of biomarkers (including natriuretic peptides). o Role of echocardiography. o Distance monitoring including telemonitoring. o Self-monitoring. Referral for invasive procedures: o Coronary revascularisation (including coronary artery bypass graft and angioplasty). Chronic Heart Failure Development of the guideline NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 Referral and approach to care. 